中重度银屑病-话题@MedSci

#中重度银屑病#

6篇内容 | 631人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2024481, encodeId=48572024481fc, content=<a href='/topic/show?id=0cf12259156' target=_blank style='color:#2F92EE;'>#中重度银屑病#</a>, objectTitle=JAAD：达到并维持接近完全或完全皮肤清除对中重度银屑病患者生活质量的影响, objectType=article, longId=294072, objectId=8e802940e27a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e802940e27a, replyNumber=0, likeNumber=39, createdTime=2022-07-11, rootId=0, userName=zhzhxiang, userId=4ba8129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e802940e27a, moduleTitle=JAAD：达到并维持接近完全或完全皮肤清除对中重度银屑病患者生活质量的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e802940e27a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024479, encodeId=670520244e921, content=<a href='/topic/show?id=0cf12259156' target=_blank style='color:#2F92EE;'>#中重度银屑病#</a>, objectTitle=Lancet：Guselkumab vs Secukinumab用于中重度银屑病, objectType=article, longId=177645, objectId=b4301e764526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4301e764526, replyNumber=0, likeNumber=36, createdTime=2019-12-05, rootId=0, userName=zhzhxiang, userId=4ba8129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4301e764526, moduleTitle=Lancet：Guselkumab vs Secukinumab用于中重度银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4301e764526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024480, encodeId=6cd9202448039, content=<a href='/topic/show?id=0cf12259156' target=_blank style='color:#2F92EE;'>#中重度银屑病#</a>, objectTitle=Lancet：Risankizumab治疗中重度银屑病患者的疗效优于阿达木单抗, objectType=article, longId=177806, objectId=ebab1e78068a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebab1e78068a, replyNumber=0, likeNumber=30, createdTime=2019-09-30, rootId=0, userName=zhzhxiang, userId=4ba8129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebab1e78068a, moduleTitle=Lancet：Risankizumab治疗中重度银屑病患者的疗效优于阿达木单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebab1e78068a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024478, encodeId=2fe920244e8d2, content=<a href='/topic/show?id=0cf12259156' target=_blank style='color:#2F92EE;'>#中重度银屑病#</a>, objectTitle=2019年美国皮肤病学（AAD）大会：Risankizumab在中重度银屑病中比Ustekinumab更有效, objectType=article, longId=162073, objectId=5eb21620e3e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5eb21620e3e2, replyNumber=0, likeNumber=41, createdTime=2019-05-28, rootId=0, userName=zhzhxiang, userId=4ba8129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5eb21620e3e2, moduleTitle=2019年美国皮肤病学（AAD）大会：Risankizumab在中重度银屑病中比Ustekinumab更有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5eb21620e3e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024477, encodeId=4cf020244e744, content=<a href='/topic/show?id=0cf12259156' target=_blank style='color:#2F92EE;'>#中重度银屑病#</a>, objectTitle=JAMA Ophthalmol：中重度银屑病患者患葡萄膜炎风险增加, objectType=article, longId=95819, objectId=236a958195c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=236a958195c, replyNumber=0, likeNumber=29, createdTime=2018-02-16, rootId=0, userName=zhzhxiang, userId=4ba8129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=236a958195c, moduleTitle=JAMA Ophthalmol：中重度银屑病患者患葡萄膜炎风险增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=236a958195c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2024476, encodeId=47bb20244e61e, content=<a href='/topic/show?id=0cf12259156' target=_blank style='color:#2F92EE;'>#中重度银屑病#</a>, objectTitle=BMC Oral Health：在北欧人群中中重度银屑病与牙周炎的关系, objectType=article, longId=46413, objectId=86324641350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86324641350, replyNumber=0, likeNumber=33, createdTime=2015-06-13, rootId=0, userName=zhzhxiang, userId=4ba8129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86324641350, moduleTitle=BMC Oral Health：在北欧人群中中重度银屑病与牙周炎的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86324641350)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

中重度银屑病

2020-05-29

zhzhxiang (审核中...)

前往app查看评论内容

#中重度银屑病#

JAAD：达到并维持接近完全或完全皮肤清除对中重度银屑病患者生活质量的影响

2022-07-11

zhzhxiang (审核中...)

前往app查看评论内容

#中重度银屑病#

Lancet：Guselkumab vs Secukinumab用于中重度银屑病

2019-12-05

zhzhxiang (审核中...)

前往app查看评论内容

#中重度银屑病#

Lancet：Risankizumab治疗中重度银屑病患者的疗效优于阿达木单抗

2019-09-30

zhzhxiang (审核中...)

前往app查看评论内容

#中重度银屑病#

2019年美国皮肤病学（AAD）大会：Risankizumab在中重度银屑病中比Ustekinumab更有效

2019-05-28

zhzhxiang (审核中...)

前往app查看评论内容

#中重度银屑病#

JAMA Ophthalmol：中重度银屑病患者患葡萄膜炎风险增加

2018-02-16

zhzhxiang (审核中...)

前往app查看评论内容

#中重度银屑病#

BMC Oral Health：在北欧人群中中重度银屑病与牙周炎的关系

2015-06-13

科室
- - 订阅+
  - 更多科室
工具
服务